Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other CRISPR ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

Oppenheimer emphasized the advancements in CRISPR’s in vivo initiatives, highlighting the comprehensive findings from the ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

The new GE technology — for which the Indian Council of Agricultural Research (ICAR) has recently been granted a patent — deploys the so-called TnpB or Transposon-associated proteins.